JPWO2021052349A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021052349A5 JPWO2021052349A5 JP2022517452A JP2022517452A JPWO2021052349A5 JP WO2021052349 A5 JPWO2021052349 A5 JP WO2021052349A5 JP 2022517452 A JP2022517452 A JP 2022517452A JP 2022517452 A JP2022517452 A JP 2022517452A JP WO2021052349 A5 JPWO2021052349 A5 JP WO2021052349A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
上記の実施形態は、権利請求される実施形態を作製及び使用する方法を、当業者に十分に開示及び説明することが意図され、本開示の範囲を限定することは意図されていない。当業者に明らかな変更は、本明細書における特許請求の範囲内である。本明細書に引用される全ての刊行物、特許及び特許出願は、それらのそれぞれが具体的に且つ独立して参照により本明細書に援用されているかのように、参照により本明細書に援用される。
本件出願は、以下の態様の発明を提供する。
(態様1)
1、2、3、4、5又は6つのアミノ酸配列を含む、ヒトGIPRに特異的に結合する抗体であって、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:
a.軽鎖CDR1アミノ酸配列:配列番号1、配列番号4、配列番号7、配列番号10、配列番号13、及び配列番号15;
b.軽鎖CDR2アミノ酸配列:配列番号2、配列番号5、配列番号8、配列番号11、及び配列番号16;
c.軽鎖CDR3アミノ酸配列:配列番号3、配列番号6、配列番号9、配列番号12、配列番号14、及び配列番号17;
d.重鎖CDR1アミノ酸配列:配列番号18、配列番号23、及び配列番号26;
e.重鎖CDR2アミノ酸配列:配列番号19、配列番号21、配列番号24、配列番号27、及び配列番号29;及び
f.重鎖CDR3アミノ酸配列:配列番号20、配列番号22、配列番号25、配列番号28、及び配列番号30
から選択される、抗体。
(態様2)
前記抗体が、1又は2つのアミノ酸配列を含み、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:
a.軽鎖CDR1アミノ酸配列:配列番号1、配列番号4、配列番号7、配列番号10、配列番号13、及び配列番号15;及び
b.重鎖CDR1アミノ酸配列:配列番号18、配列番号23、及び配列番号26から選択される、態様1に記載の抗体。
(態様3)
前記抗体が、1又は2つのアミノ酸配列を含み又はさらに含み、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:
a.軽鎖CDR2アミノ酸配列:配列番号2、配列番号5、配列番号8、配列番号11、及び配列番号16;及び
b.重鎖CDR2アミノ酸配列:配列番号19、配列番号21、配列番号24、配列番号27、及び配列番号29
から選択される、態様1又は2に記載の抗体。
(態様4)
前記抗体が、1又は2つのアミノ酸配列を含むか又はさらに含み、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:
a.軽鎖CDR3アミノ酸配列:配列番号3、配列番号6、配列番号9、配列番号12、配列番号14、及び配列番号17;及び
b.重鎖CDR3アミノ酸配列:配列番号20、配列番号22、配列番号25、配列番号28、及び配列番号30
から選択される、態様1~態様3のいずれか一項に記載の抗体。
(態様5)
前記抗体が、1又は2つのアミノ酸配列を含むか又はさらに含み、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:配列番号1、配列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7、配列番号8、配列番号9、配列番号10、配列番号11、配列番号12、配列番号13、配列番号14、配列番号15、配列番号16、及び配列番号17から選択される、態様1~態様4のいずれか一項に記載の抗体。
(態様6)
前記抗体が、1又は2つのアミノ酸配列を含むか又はさらに含み、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:配列番号18、配列番号19、配列番号20、配列番号21、配列番号22、配列番号23、配列番号24、配列番号25、配列番号26、配列番号27、配列番号28、配列番号29、及び配列番号30から選択される、態様1~態様5のいずれか一項に記載の抗体。
(態様7)
前記抗体が、以下のリスト:配列番号1及び配列番号18、配列番号4及び配列番号18、配列番号7及び配列番号23、配列番号10及び配列番号26、配列番号13及び配列番号26、及び配列番号15及び配列番号26から独立して選択される軽鎖及び重鎖CDR1アミノ酸配列の組合せを含むか又はさらに含む、態様1~態様6のいずれか一項に記載の抗体。
(態様8)
前記抗体が、以下のリスト:配列番号2及び配列番号19、配列番号5及び配列番号21、配列番号8及び配列番号24、配列番号11及び配列番号27、及び配列番号16及び配列番号29から独立して選択される軽鎖及び重鎖CDR2アミノ酸配列の組合せを含むか又はさらに含む、態様1~態様7のいずれか一項に記載の抗体。
(態様9)
前記抗体が、以下のリスト:配列番号3及び配列番号20、配列番号6及び配列番号22、配列番号9及び配列番号25、配列番号12及び配列番号28、配列番号14及び配列番号28、及び配列番号17及び配列番号30から独立して選択される軽鎖及び重鎖CDR3アミノ酸配列の組合せを含むか又はさらに含む、態様1~態様8のいずれか一項に記載の抗体。
(態様10)
前記抗体が、
(a)軽鎖CDR1アミノ酸配列:配列番号1;
軽鎖CDR2アミノ酸配列:配列番号2;
軽鎖CDR3アミノ酸配列:配列番号3;
重鎖CDR1アミノ酸配列:配列番号18;
重鎖CDR2アミノ酸配列:配列番号19;及び
重鎖CDR3アミノ酸配列:配列番号20;
(b)軽鎖CDR1アミノ酸配列:配列番号4;
軽鎖CDR2アミノ酸配列:配列番号5;
軽鎖CDR3アミノ酸配列:配列番号6;
重鎖CDR1アミノ酸配列:配列番号18;
重鎖CDR2アミノ酸配列:配列番号21;及び
重鎖CDR3アミノ酸配列:配列番号22;
(c)軽鎖CDR1アミノ酸配列:配列番号7;
軽鎖CDR2アミノ酸配列:配列番号8;
軽鎖CDR3アミノ酸配列:配列番号9;
重鎖CDR1アミノ酸配列:配列番号23;
重鎖CDR2アミノ酸配列:配列番号24;及び
重鎖CDR3アミノ酸配列:配列番号25;
(d)軽鎖CDR1アミノ酸配列:配列番号10;
軽鎖CDR2アミノ酸配列:配列番号11;
軽鎖CDR3アミノ酸配列:配列番号12;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号27;及び
重鎖CDR3アミノ酸配列:配列番号28;
(e)軽鎖CDR1アミノ酸配列:配列番号13;
軽鎖CDR2アミノ酸配列:配列番号11;
軽鎖CDR3アミノ酸配列:配列番号14;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号27;及び
重鎖CDR3アミノ酸配列:配列番号28;
(f)軽鎖CDR1アミノ酸配列:配列番号15;
軽鎖CDR2アミノ酸配列:配列番号16;
軽鎖CDR3アミノ酸配列:配列番号17;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号29;及び
重鎖CDR3アミノ酸配列:配列番号30
を含む、態様1~態様9のいずれか一項に記載の抗体。
(態様11)
前記抗体が、
軽鎖CDR1アミノ酸配列:配列番号15;
軽鎖CDR2アミノ酸配列:配列番号16;
軽鎖CDR3アミノ酸配列:配列番号17;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号29;及び
重鎖CDR3アミノ酸配列:配列番号30
を含む、態様10に記載の抗体。
(態様12)
前記抗体が、1又は2つのアミノ酸配列を含み、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:
a.軽鎖可変アミノ酸ドメイン配列:配列番号61、配列番号62、配列番号63、配列番号64、配列番号65、配列番号66、配列番号67、配列番号68、配列番号69、配列番号70、及び配列番号71;及びいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるアミノ酸配列;及び
b.重鎖可変アミノ酸ドメイン配列:配列番号72、配列番号73、配列番号74、配列番号75、配列番号76、配列番号77、配列番号78、配列番号79、及び配列番号80;及びいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるアミノ酸配列
から選択される、態様1~態様11のいずれか一項に記載の抗体。
(態様13)
前記抗体コードポリヌクレオチド配列が、1又は2つのポリヌクレオチド配列を含み、ここで、各ポリヌクレオチド配列が、独立して、以下に列挙されるポリヌクレオチド配列:
a.軽鎖可変ドメインポリヌクレオチドコード配列:配列番号81、配列番号82、配列番号83、配列番号84、配列番号85、配列番号86、配列番号87、配列番号88、配列番号89、配列番号90、及び配列番号91;及びいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるポリヌクレオチド配列;及び
b.重鎖可変ドメインコードポリヌクレオチド配列:配列番号92、配列番号93、配列番号94、配列番号95、配列番号96、配列番号97、配列番号98、配列番号99、及び配列番号100;及びいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるポリヌクレオチド配列から選択される、態様1~態様12のいずれか一項に記載の抗体。
(態様14)
前記抗体が、以下のリスト:配列番号61、配列番号62、配列番号63、配列番号64、配列番号65、配列番号66、配列番号67、配列番号68、配列番号69、配列番号70、及び配列番号71から独立して選択されるアミノ酸配列を含むか又はさらに含む、態様1~態様13のいずれか一項に記載の抗体。
(態様15)
前記抗体が、以下のリスト:配列番号72、配列番号73、配列番号74、配列番号75、配列番号76、配列番号77、配列番号78、配列番号79、及び配列番号80から独立して選択されるアミノ酸配列を含むか又はさらに含む、態様1~態様14のいずれか一項に記載の抗体。
(態様16)
前記抗体が、以下のリスト:配列番号61及び配列番号72、配列番号62及び配列番号73、配列番号63及び配列番号74、配列番号64及び配列番号74、配列番号65及び配列番号75、配列番号66及び配列番号76、配列番号67及び配列番号77、配列番号68及び配列番号77、配列番号69及び配列番号78、配列番号70及び配列番号79、及び配列番号71及び配列番号80から独立して選択される軽鎖及び重鎖可変ドメインアミノ酸配列の組合せを含む、態様1~態様15のいずれか一項に記載の抗体。
(態様17)
前記抗体が、以下のリスト:配列番号62、配列番号63、配列番号64、配列番号66、配列番号67、配列番号68、配列番号73、配列番号74、配列番号76、及び配列番号77から独立して選択されるアミノ酸配列を含むか又はさらに含む、態様16に記載の抗体。
(態様18)
前記抗体が、以下のリスト:配列番号62及び配列番号73、配列番号63及び配列番号74、配列番号64及び配列番号74、配列番号66及び配列番号76、配列番号67及び配列番号77、及び配列番号68及び配列番号77から独立して選択される軽鎖及び重鎖可変ドメインアミノ酸配列の組合せを含む、態様16に記載の抗体。
(態様19)
前記抗体が、アミノ酸配列配列番号67又は配列番号77を含む、態様16に記載の抗体。
(態様20)
前記抗体が、アミノ酸配列配列番号67及び配列番号77の組合せを含む、態様16に記載の抗体。
(態様21)
前記抗体が、1又は2つのアミノ酸配列を含み、ここで、各アミノ酸配列が、独立して、以下に列挙されるアミノ酸配列:
a.軽鎖定常ドメインアミノ酸配列:配列番号101及び配列番号102;及び
b.重鎖定常ドメインアミノ酸配列:配列番号103、配列番号104及び配列番号124
から選択される、態様1~態様20のいずれか一項に記載の抗体。
(態様22)
前記抗体が、マウスGIPR抗体又はヒト化GIPR抗体である、態様1~態様21のいずれか一項に記載の抗体。
(態様23)
前記抗体が、GIPRモノクローナル抗体である、態様1~態様22のいずれか一項に記載の抗体。
(態様24)
前記抗体が、以下のリスト:配列番号61及び配列番号72、配列番号62及び配列番号73、配列番号63及び配列番号74、配列番号64及び配列番号74、配列番号65及び配列番号75、配列番号66及び配列番号76、配列番号67及び配列番号77、配列番号68及び配列番号77、配列番号69及び配列番号78、配列番号70及び配列番号79、及び配列番号71及び配列番号80から独立して選択されるアミノ酸配列の組合せを含むモノクローナル抗体である、態様1~態様23のいずれか一項に記載の抗体。
(態様25)
前記抗体が、以下のリスト:配列番号61及び配列番号72、配列番号62及び配列番号73、配列番号63及び配列番号74、配列番号64及び配列番号74、配列番号65及び配列番号75、配列番号66及び配列番号76、配列番号67及び配列番号77、配列番号68及び配列番号77、配列番号69及び配列番号78、配列番号70及び配列番号79、及び配列番号71及び配列番号80から独立して選択されるアミノ酸配列の組合せを含むモノクローナル抗体である、態様1~態様23のいずれか一項に記載の抗体。
(態様26)
前記抗体が、組合せV1W1(配列番号125及び配列番号127)、V1W2(配列番号125及び配列番号128)、V1W3(配列番号125及び配列番号129)、V1W4(配列番号125及び配列番号130)、V1W5(配列番号125及び配列番号131)、V1W6(配列番号125及び配列番号132)、V1W7(配列番号125及び配列番号133)、V1W8(配列番号125及び配列番号134)、V1W9(配列番号125及び配列番号135)、V2W1(配列番号126及び配列番号127)、V2W2(配列番号126及び配列番号128)、V2W3(配列番号126及び配列番号129)、V2W4(配列番号126及び配列番号130)、V2W5(配列番号126及び配列番号131)、V2W6(配列番号126及び配列番号132)、V2W7(配列番号126及び配列番号133)、V2W8(配列番号126及び配列番号134)、又はV2W9(配列番号126及び配列番号135)の抗体を含む、態様1~態様25のいずれか一項に記載の抗体。
(態様27)
前記抗体が、組合せV1W4(配列番号125及び配列番号130)、V1W5(配列番号125及び配列番号131)、又はV1W6(配列番号125及び配列番号132)の抗体を含む、態様1~態様25のいずれか一項に記載の抗体。
(態様28)
前記抗体が、組合せV1W5(配列番号125及び配列番号131)の抗体を含む、態様1~態様25のいずれか一項に記載の抗体。
(態様29)
前記抗体が、1つ又は複数の以下の特性:
a.ヒトGIPRに結合する際に、参照GIPR抗体と同じか又はそれより良好なKdを提供すること;
b.GIPによって活性化されるヒトGIPRに拮抗する際に、参照GIPR抗体と同じか又はそれより良好なIC
50
を提供すること;及び
c.ヒトGIPRに対して参照GIPR抗体と結合に関して交差競合すること
を含む、態様1~態様28のいずれか一項に記載の抗体。
(態様30)
ヒトGIPRに対して前記参照GIPR抗体と結合に関して交差競合する前記抗体、態様29に記載の抗体。
(態様31)
前記参照GIPR抗体が、態様1~態様28のいずれか一項に記載の抗体を含む、態様29又は態様30に記載の抗体。
(態様32)
前記参照GIPR抗体が、軽鎖可変ドメインアミノ酸配列配列番号67及び重鎖可変ドメインアミノ酸配列配列番号77の組合せを含む、態様31に記載の抗体。
(態様33)
その特徴は、前記抗体が、マウス抗体、ヒト抗体、ヒト化抗体、キメラ抗体、モノクローナル抗体、ポリクローナル抗体、組み換え抗体、抗原結合抗体フラグメント、一本鎖抗体、二重鎖抗体、三重鎖抗体、四重鎖抗体、Fabフラグメント、F(ab’)xフラグメント、構造ドメイン抗体、IgD抗体、IgE抗体、IgM抗体、IgG1抗体、IgG2抗体、IgG3抗体、又はIgG4抗体から選択される、ことである態様1~態様32のいずれか一項に記載の抗体。
(態様34)
前記抗体が、ヒトGIPのシグナル伝達を低減する際に、約1nM~200nM又は1nM~100nMのIC50を有する、態様1~態様33のいずれか一項に記載の抗体。
(態様35)
GLP-1融合タンパク質であって、前記融合タンパク質が、態様1~34のいずれか一項に記載のGIPR抗体、及び1、2、3、4、5、6、7又は8つのGLP-1フラグメント又は逆GLP-1フラグメントを含み;前記融合タンパク質が、ペプチドリンカーを介して、GLP-1フラグメントのカルボキシ末端を、GIPR抗体の軽鎖若しくは重鎖のアミノ末端と結合するか、又は逆GLP-1フラグメントのアミノ末端を、前記GIPR抗体の軽鎖若しくは重鎖のカルボキシ末端と結合するという構造的特徴を有するGLP-1融合タンパク質。
(態様36)
前記融合タンパク質が、GIPR抗体及び1、2、3又は4つのGLP-1フラグメントを含み;前記融合タンパク質が、ペプチドリンカーを介して、GLP-1フラグメントのカルボキシ末端を、GIPR抗体の軽鎖若しくは重鎖のアミノ末端と結合する、態様35に記載の融合タンパク質。
(態様37)
前記融合タンパク質が、GIPR抗体及び1つ、2つ、3つ又は4つの逆GLP-1フラグメントを含み;前記融合タンパク質が、ペプチドリンカーを介して、逆GLP-1フラグメントのアミノ末端を、GIPR抗体の軽鎖若しくは重鎖のカルボキシ末端と結合する、態様35に記載の融合タンパク質。
(態様38)
前記融合タンパク質がGIPR抗体及び2つのGLP-1フラグメントを含み;前記融合タンパク質が、ペプチドリンカーを介してGLP-1フラグメントのカルボキシ末端をGIPR抗体の軽鎖又は重鎖のアミノ末端に結合する、態様35に記載の融合タンパク質。
(態様39)
前記融合タンパク質がGIPR抗体及び2つの逆GLP-1フラグメントを含み;前記融合タンパク質が、ペプチドリンカーを介して逆GLP-1フラグメントのアミノ末端をGIPR抗体の軽鎖又は重鎖のカルボキシ末端に結合する、態様35に記載の融合タンパク質。
(態様40)
前記GIPR抗体、GLP-1フラグメント及びペプチドリンカーが、以下の方法のうちの1つにおいて融合されて前記融合タンパク質を形成し:
ペプチドリンカーを介して、GLP-1フラグメントのカルボキシ末端が、GIPR抗体の軽鎖のアミノ末端に融合され:N’-GLP-1-リンカー-R-C’;
ペプチドリンカーを介して、GLP-1フラグメントのカルボキシ末端が、GIPR抗体の重鎖のアミノ末端に融合され:N’-GLP-1-リンカー-R-C’;
ここで:N’が、前記融合タンパク質のポリペプチド鎖のアミノ末端を表し、C’が、前記融合タンパク質のポリペプチド鎖のカルボキシ末端を表し、GLP-1が、GLP-1フラグメントを表し、Rが、態様1~34のいずれか一項に記載のGIPR抗体の軽鎖又は重鎖のアミノ酸配列を表し、リンカーが、ポリペプチドリンカーを表す、態様35に記載の融合タンパク質。
(態様41)
前記ペプチドリンカーが、配列番号110、配列番号111、及び配列番号112から独立して選択される、完全長、部分的、又は反復アミノ酸配列を含む、態様35~40のいずれか一項に記載のGLP-1融合タンパク質。
(態様42)
前記GLP-1フラグメントが、配列番号105、配列番号106、配列番号107、配列番号108、及び配列番号109から独立して選択されるアミノ酸配列を含むか;又は前記逆GLP-1フラグメントが、配列番号119、配列番号120、配列番号121、配列番号122、及び配列番号123から独立して選択されるアミノ酸配列を含む、態様35~40のいずれか一項に記載のGLP-1融合タンパク質。
(態様43)
態様1~34のいずれか一項に記載のGIPR抗体、又は態様35~42のいずれか一項に記載のGLP-1融合タンパク質をコードするポリヌクレオチド。
(態様44)
態様43に記載のポリヌクレオチドを含むベクター。
(態様45)
態様44に記載のベクターを含む宿主細胞。
(態様46)
薬学的に許容できる担体と混合された、態様1~34のいずれか一項に記載のGIPR抗体又は態様35~42のいずれか一項に記載のGLP-1融合タンパク質を含む医薬組成物。
(態様47)
非アルコール性脂肪肝疾患を予防又は処置するための薬剤の調製における、態様1~34のいずれか一項に記載のGIPR抗体又は態様35~42のいずれか一項に記載のGLP-1融合タンパク質を含む医薬組成物の使用。
(態様48)
2型糖尿病を予防又は処置するための薬剤の調製における、態様1~34のいずれか一項に記載のGIPR抗体又は態様35~42のいずれか一項に記載のGLP-1融合タンパク質を含む医薬組成物の使用。
(態様49)
肥満及び肥満関連疾患を体重減少又は処置するための薬剤の調製における、態様1~34のいずれか一項に記載のGIPR抗体又は態様35~42のいずれか一項に記載のGLP-1融合タンパク質を含む医薬組成物の使用。
(態様50)
非アルコール性脂肪肝疾患、肥満、又は2型糖尿病のうちの2つ以上の疾患を同時に処置するための薬剤の調製における、態様1~34のいずれか一項に記載のGIPR抗体又は態様35~42のいずれか一項に記載のGLP-1融合タンパク質を含む医薬組成物の使用。
(態様51)
前記医薬組成物が、静脈内に又は皮下に投与されるものである、態様47~50のいずれか一項に記載の使用。
The embodiments described above are intended to fully disclose and explain to those skilled in the art how to make and use the claimed embodiments, and are not intended to limit the scope of the present disclosure. Modifications obvious to those skilled in the art are within the scope of the claims herein. All publications, patents, and patent applications cited herein are herein incorporated by reference as if each were specifically and independently incorporated by reference. be done.
The present application provides the following aspects of the invention.
(Aspect 1)
An antibody that specifically binds to human GIPR comprising 1, 2, 3, 4, 5 or 6 amino acid sequences, wherein each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain CDR1 amino acid sequences: SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO: 15;
b. Light chain CDR2 amino acid sequences: SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11, and SEQ ID NO: 16;
c. Light chain CDR3 amino acid sequences: SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 14, and SEQ ID NO: 17;
d. Heavy chain CDR1 amino acid sequences: SEQ ID NO: 18, SEQ ID NO: 23, and SEQ ID NO: 26;
e. Heavy chain CDR2 amino acid sequences: SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 27, and SEQ ID NO: 29; and
f. Heavy chain CDR3 amino acid sequence: SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, and SEQ ID NO: 30
An antibody selected from.
(Aspect 2)
The antibody comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain CDR1 amino acid sequences: SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO: 15;
b. The antibody according to aspect 1, wherein the heavy chain CDR1 amino acid sequence is selected from: SEQ ID NO: 18, SEQ ID NO: 23, and SEQ ID NO: 26.
(Aspect 3)
The antibody comprises or further comprises one or two amino acid sequences, wherein each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain CDR2 amino acid sequences: SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11, and SEQ ID NO: 16; and
b. Heavy chain CDR2 amino acid sequence: SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 27, and SEQ ID NO: 29
The antibody according to aspect 1 or 2, selected from:
(Aspect 4)
The antibody comprises or further comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain CDR3 amino acid sequences: SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 14, and SEQ ID NO: 17;
b. Heavy chain CDR3 amino acid sequence: SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, and SEQ ID NO: 30
The antibody according to any one of aspects 1 to 3, selected from:
(Aspect 5)
The antibody comprises or further comprises one or two amino acid sequences, wherein each amino acid sequence independently comprises the amino acid sequences listed below: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: No. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16 , and SEQ ID NO: 17.
(Aspect 6)
The antibody comprises or further comprises one or two amino acid sequences, wherein each amino acid sequence independently comprises the following listed amino acid sequences: SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30, Antibody according to any one of the above.
(Aspect 7)
The antibodies have the following list: SEQ ID NO. 1 and SEQ ID NO. 18, SEQ ID NO. 4 and SEQ ID NO. 18, SEQ ID NO. 7 and SEQ ID NO. 23, SEQ ID NO. 10 and SEQ ID NO. 26, SEQ ID NO. 13 and SEQ ID NO. 15 and SEQ ID NO: 26, comprising or further comprising a combination of light chain and heavy chain CDR1 amino acid sequences independently selected from SEQ ID NO: 26.
(Aspect 8)
The antibodies are independent from the following list: SEQ ID NO: 2 and SEQ ID NO: 19, SEQ ID NO: 5 and SEQ ID NO: 21, SEQ ID NO: 8 and SEQ ID NO: 24, SEQ ID NO: 11 and SEQ ID NO: 27, and SEQ ID NO: 16 and SEQ ID NO: 29. 8. The antibody according to any one of aspects 1 to 7, comprising or further comprising a combination of light chain and heavy chain CDR2 amino acid sequences selected as follows.
(Aspect 9)
The antibodies have the following list: SEQ ID NO:3 and SEQ ID NO:20, SEQ ID NO:6 and SEQ ID NO:22, SEQ ID NO:9 and SEQ ID NO:25, SEQ ID NO:12 and SEQ ID NO:28, SEQ ID NO:14 and SEQ ID NO:28, and 17 and SEQ ID NO: 30, comprising or further comprising a combination of light chain and heavy chain CDR3 amino acid sequences independently selected from SEQ ID NO: 30.
(Aspect 10)
The antibody is
(a) Light chain CDR1 amino acid sequence: SEQ ID NO: 1;
Light chain CDR2 amino acid sequence: SEQ ID NO: 2;
Light chain CDR3 amino acid sequence: SEQ ID NO: 3;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 18;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 19; and
Heavy chain CDR3 amino acid sequence: SEQ ID NO: 20;
(b) Light chain CDR1 amino acid sequence: SEQ ID NO: 4;
Light chain CDR2 amino acid sequence: SEQ ID NO: 5;
Light chain CDR3 amino acid sequence: SEQ ID NO: 6;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 18;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 21; and
Heavy chain CDR3 amino acid sequence: SEQ ID NO: 22;
(c) Light chain CDR1 amino acid sequence: SEQ ID NO: 7;
Light chain CDR2 amino acid sequence: SEQ ID NO: 8;
Light chain CDR3 amino acid sequence: SEQ ID NO: 9;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 23;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 24; and
Heavy chain CDR3 amino acid sequence: SEQ ID NO: 25;
(d) Light chain CDR1 amino acid sequence: SEQ ID NO: 10;
Light chain CDR2 amino acid sequence: SEQ ID NO: 11;
Light chain CDR3 amino acid sequence: SEQ ID NO: 12;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 27; and
Heavy chain CDR3 amino acid sequence: SEQ ID NO: 28;
(e) Light chain CDR1 amino acid sequence: SEQ ID NO: 13;
Light chain CDR2 amino acid sequence: SEQ ID NO: 11;
Light chain CDR3 amino acid sequence: SEQ ID NO: 14;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 27; and
Heavy chain CDR3 amino acid sequence: SEQ ID NO: 28;
(f) Light chain CDR1 amino acid sequence: SEQ ID NO: 15;
Light chain CDR2 amino acid sequence: SEQ ID NO: 16;
Light chain CDR3 amino acid sequence: SEQ ID NO: 17;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 29; and
Heavy chain CDR3 amino acid sequence: SEQ ID NO: 30
The antibody according to any one of aspects 1 to 9, comprising:
(Aspect 11)
The antibody is
Light chain CDR1 amino acid sequence: SEQ ID NO: 15;
Light chain CDR2 amino acid sequence: SEQ ID NO: 16;
Light chain CDR3 amino acid sequence: SEQ ID NO: 17;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 29; and
Heavy chain CDR3 amino acid sequence: SEQ ID NO: 30
The antibody according to aspect 10, comprising:
(Aspect 12)
The antibody comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain variable amino acid domain sequences: SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, and SEQ ID NO: 71; and an amino acid sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to one of any of the above sequences; and
b. Heavy chain variable amino acid domain sequences: SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, and SEQ ID NO: 80; and any of the above. an amino acid sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to one of the sequences
The antibody according to any one of aspects 1 to 11, selected from:
(Aspect 13)
The antibody encoding polynucleotide sequence comprises one or two polynucleotide sequences, where each polynucleotide sequence is independently a polynucleotide sequence listed below:
a. Light chain variable domain polynucleotide coding sequences: SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, and and a polynucleotide sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO: 91; and any one of the above sequences; and
b. Heavy chain variable domain encoding polynucleotide sequences: SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, and SEQ ID NO: 100; and any An antibody according to any one of aspects 1 to 12, selected from polynucleotide sequences that are at least 80%, at least 85%, at least 90%, or at least 95% identical to one of the above sequences.
(Aspect 14)
The antibodies have the following list: SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, and 14. An antibody according to any one of aspects 1 to 13, comprising or further comprising an amino acid sequence independently selected from number 71.
(Aspect 15)
The antibody is independently selected from the following list: SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, and SEQ ID NO: 80. An antibody according to any one of aspects 1 to 14, comprising or further comprising an amino acid sequence comprising:
(Aspect 16)
The antibodies have the following list: SEQ ID NO: 61 and SEQ ID NO: 72, SEQ ID NO: 62 and SEQ ID NO: 73, SEQ ID NO: 63 and SEQ ID NO: 74, SEQ ID NO: 64 and SEQ ID NO: 74, SEQ ID NO: 65 and SEQ ID NO: 75, SEQ ID NO: 66 and SEQ ID NO: 76, SEQ ID NO: 67 and SEQ ID NO: 77, SEQ ID NO: 68 and SEQ ID NO: 77, SEQ ID NO: 69 and SEQ ID NO: 78, SEQ ID NO: 70 and SEQ ID NO: 79, and SEQ ID NO: 71 and SEQ ID NO: 80 16. An antibody according to any one of aspects 1 to 15, comprising a selected combination of light chain and heavy chain variable domain amino acid sequences.
(Aspect 17)
The antibody is independent of the following list: SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, and SEQ ID NO: 77. 17. The antibody according to aspect 16, comprising or further comprising an amino acid sequence selected as:
(Aspect 18)
The antibodies have the following list: SEQ ID NO:62 and SEQ ID NO:73, SEQ ID NO:63 and SEQ ID NO:74, SEQ ID NO:64 and SEQ ID NO:74, SEQ ID NO:66 and SEQ ID NO:76, SEQ ID NO:67 and SEQ ID NO:77, and SEQ ID NO:67 and SEQ ID NO:77; 17. The antibody according to aspect 16, comprising a combination of light chain and heavy chain variable domain amino acid sequences independently selected from No. 68 and SEQ ID No. 77.
(Aspect 19)
17. The antibody according to aspect 16, wherein the antibody comprises the amino acid sequence SEQ ID NO: 67 or SEQ ID NO: 77.
(Aspect 20)
17. The antibody of aspect 16, wherein said antibody comprises the combination of amino acid sequences SEQ ID NO: 67 and SEQ ID NO: 77.
(Aspect 21)
The antibody comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain constant domain amino acid sequence: SEQ ID NO: 101 and SEQ ID NO: 102; and
b. Heavy chain constant domain amino acid sequence: SEQ ID NO: 103, SEQ ID NO: 104 and SEQ ID NO: 124
The antibody according to any one of aspects 1 to 20, selected from:
(Aspect 22)
The antibody according to any one of aspects 1 to 21, wherein the antibody is a mouse GIPR antibody or a humanized GIPR antibody.
(Aspect 23)
The antibody according to any one of aspects 1 to 22, wherein the antibody is a GIPR monoclonal antibody.
(Aspect 24)
The antibodies have the following list: SEQ ID NO: 61 and SEQ ID NO: 72, SEQ ID NO: 62 and SEQ ID NO: 73, SEQ ID NO: 63 and SEQ ID NO: 74, SEQ ID NO: 64 and SEQ ID NO: 74, SEQ ID NO: 65 and SEQ ID NO: 75, SEQ ID NO: 66 and SEQ ID NO: 76, SEQ ID NO: 67 and SEQ ID NO: 77, SEQ ID NO: 68 and SEQ ID NO: 77, SEQ ID NO: 69 and SEQ ID NO: 78, SEQ ID NO: 70 and SEQ ID NO: 79, and SEQ ID NO: 71 and SEQ ID NO: 80 The antibody according to any one of aspects 1 to 23, which is a monoclonal antibody comprising a selected combination of amino acid sequences.
(Aspect 25)
The antibodies have the following list: SEQ ID NO: 61 and SEQ ID NO: 72, SEQ ID NO: 62 and SEQ ID NO: 73, SEQ ID NO: 63 and SEQ ID NO: 74, SEQ ID NO: 64 and SEQ ID NO: 74, SEQ ID NO: 65 and SEQ ID NO: 75, SEQ ID NO: 66 and SEQ ID NO: 76, SEQ ID NO: 67 and SEQ ID NO: 77, SEQ ID NO: 68 and SEQ ID NO: 77, SEQ ID NO: 69 and SEQ ID NO: 78, SEQ ID NO: 70 and SEQ ID NO: 79, and SEQ ID NO: 71 and SEQ ID NO: 80 The antibody according to any one of aspects 1 to 23, which is a monoclonal antibody comprising a selected combination of amino acid sequences.
(Aspect 26)
The antibodies include the combinations V1W1 (SEQ ID NO: 125 and SEQ ID NO: 127), V1W2 (SEQ ID NO: 125 and SEQ ID NO: 128), V1W3 (SEQ ID NO: 125 and SEQ ID NO: 129), V1W4 (SEQ ID NO: 125 and SEQ ID NO: 130), V1W5 (SEQ ID NO: 125 and SEQ ID NO: 131), V1W6 (SEQ ID NO: 125 and SEQ ID NO: 132), V1W7 (SEQ ID NO: 125 and SEQ ID NO: 133), V1W8 (SEQ ID NO: 125 and SEQ ID NO: 134), V1W9 (SEQ ID NO: 125 and SEQ ID NO: 134), No. 135), V2W1 (SEQ ID No. 126 and SEQ ID No. 127), V2W2 (SEQ ID No. 126 and SEQ ID No. 128), V2W3 (SEQ ID No. 126 and SEQ ID No. 129), V2W4 (SEQ ID No. 126 and SEQ ID No. 130), V2W5 ( SEQ ID NO: 126 and SEQ ID NO: 131), V2W6 (SEQ ID NO: 126 and SEQ ID NO: 132), V2W7 (SEQ ID NO: 126 and SEQ ID NO: 133), V2W8 (SEQ ID NO: 126 and SEQ ID NO: 134), or V2W9 (SEQ ID NO: 126 and SEQ ID NO: 134), 135). The antibody according to any one of aspects 1 to 25.
(Aspect 27)
Any of aspects 1 to 25, wherein the antibody comprises antibodies of the combination V1W4 (SEQ ID NO: 125 and SEQ ID NO: 130), V1W5 (SEQ ID NO: 125 and SEQ ID NO: 131), or V1W6 (SEQ ID NO: 125 and SEQ ID NO: 132). The antibody according to item 1.
(Aspect 28)
26. The antibody according to any one of aspects 1 to 25, wherein said antibody comprises antibodies of combination V1W5 (SEQ ID NO: 125 and SEQ ID NO: 131).
(Aspect 29)
The antibody has one or more of the following properties:
a. provide the same or better Kd in binding to human GIPR than a reference GIPR antibody;
b. provide an IC 50 equal to or better than a reference GIPR antibody in antagonizing human GIPR activated by GIP ; and
c. Cross-compete for binding with a reference GIPR antibody to human GIPR
The antibody according to any one of aspects 1 to 28, comprising:
(Aspect 30)
30. The antibody of embodiment 29, said antibody cross-competing for binding with said reference GIPR antibody for human GIPR.
(Aspect 31)
The antibody according to aspect 29 or aspect 30, wherein the reference GIPR antibody comprises an antibody according to any one of aspects 1 to 28.
(Aspect 32)
32. The antibody of aspect 31, wherein the reference GIPR antibody comprises the combination of light chain variable domain amino acid sequence SEQ ID NO: 67 and heavy chain variable domain amino acid sequence SEQ ID NO: 77.
(Aspect 33)
The characteristics are that the antibodies can be mouse antibodies, human antibodies, humanized antibodies, chimeric antibodies, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, antigen-binding antibody fragments, single chain antibodies, double chain antibodies, triple chain antibodies, four chain antibodies, Embodiment 1 selected from heavy chain antibodies, Fab fragments, F(ab')x fragments, structural domain antibodies, IgD antibodies, IgE antibodies, IgM antibodies, IgG1 antibodies, IgG2 antibodies, IgG3 antibodies, or IgG4 antibodies. -An antibody according to any one of embodiment 32.
(Aspect 34)
34. The antibody according to any one of aspects 1 to 33, wherein the antibody has an IC50 of about 1 nM to 200 nM or 1 nM to 100 nM in reducing human GIP signaling.
(Aspect 35)
A GLP-1 fusion protein, wherein said fusion protein comprises a GIPR antibody according to any one of aspects 1 to 34 and 1, 2, 3, 4, 5, 6, 7 or 8 GLP-1 fragments. or a reverse GLP-1 fragment; the fusion protein joins the carboxy terminus of the GLP-1 fragment to the amino terminus of the light or heavy chain of the GIPR antibody via a peptide linker; A GLP-1 fusion protein having the structural feature that the amino terminus of the fragment is linked to the carboxy terminus of the light chain or heavy chain of the GIPR antibody.
(Aspect 36)
The fusion protein comprises a GIPR antibody and one, two, three or four GLP-1 fragments; 36. A fusion protein according to aspect 35, which binds to the amino terminus of the chain.
(Aspect 37)
the fusion protein comprises a GIPR antibody and one, two, three or four reverse GLP-1 fragments; 36. The fusion protein according to aspect 35, which binds to the carboxy terminus of the light chain or heavy chain of.
(Aspect 38)
Embodiments wherein the fusion protein comprises a GIPR antibody and two GLP-1 fragments; the fusion protein connects the carboxy terminus of the GLP-1 fragment to the amino terminus of the light chain or heavy chain of the GIPR antibody via a peptide linker. 35. The fusion protein according to 35.
(Aspect 39)
The fusion protein comprises a GIPR antibody and two reverse GLP-1 fragments; the fusion protein connects the amino terminus of the reverse GLP-1 fragment to the carboxy terminus of the light or heavy chain of the GIPR antibody via a peptide linker. , the fusion protein according to aspect 35.
(Aspect 40)
The GIPR antibody, GLP-1 fragment and peptide linker are fused to form the fusion protein in one of the following ways:
The carboxy terminus of the GLP-1 fragment is fused to the amino terminus of the light chain of the GIPR antibody via a peptide linker: N'-GLP-1-linker-RC';
The carboxy terminus of the GLP-1 fragment is fused to the amino terminus of the heavy chain of the GIPR antibody via a peptide linker: N'-GLP-1-linker-RC';
where: N' represents the amino terminus of the polypeptide chain of said fusion protein, C' represents the carboxy terminus of the polypeptide chain of said fusion protein, GLP-1 represents a GLP-1 fragment, and R 36. The fusion protein according to aspect 35, wherein represents the amino acid sequence of a light chain or heavy chain of a GIPR antibody according to any one of aspects 1 to 34, and the linker represents a polypeptide linker.
(Aspect 41)
41. According to any one of aspects 35 to 40, the peptide linker comprises a full-length, partial or repetitive amino acid sequence independently selected from SEQ ID NO: 110, SEQ ID NO: 111 and SEQ ID NO: 112. GLP-1 fusion protein.
(Aspect 42)
said GLP-1 fragment comprises an amino acid sequence independently selected from SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, and SEQ ID NO: 109; 41. A GLP-1 fusion protein according to any one of aspects 35 to 40, comprising an amino acid sequence independently selected from No. 119, SEQ ID No. 120, SEQ ID No. 121, SEQ ID No. 122, and SEQ ID No. 123.
(Aspect 43)
A polynucleotide encoding a GIPR antibody according to any one of aspects 1 to 34 or a GLP-1 fusion protein according to any one of aspects 35 to 42.
(Aspect 44)
A vector comprising the polynucleotide according to aspect 43.
(Aspect 45)
A host cell comprising the vector according to aspect 44.
(Aspect 46)
A pharmaceutical composition comprising a GIPR antibody according to any one of aspects 1 to 34 or a GLP-1 fusion protein according to any one of aspects 35 to 42, mixed with a pharmaceutically acceptable carrier.
(Aspect 47)
GIPR antibody according to any one of aspects 1 to 34 or GLP-1 fusion protein according to any one of aspects 35 to 42 in the preparation of a medicament for preventing or treating non-alcoholic fatty liver disease Use of a pharmaceutical composition comprising.
(Aspect 48)
A medicament comprising a GIPR antibody according to any one of aspects 1 to 34 or a GLP-1 fusion protein according to any one of aspects 35 to 42, in the preparation of a medicament for preventing or treating type 2 diabetes. Use of the composition.
(Aspect 49)
GIPR antibody according to any one of aspects 1 to 34 or GLP-1 fusion protein according to any one of aspects 35 to 42, in the preparation of a medicament for weight loss or treatment of obesity and obesity-related diseases. Use of a pharmaceutical composition comprising.
(Aspect 50)
GIPR antibody according to any one of embodiments 1 to 34 or embodiments 35 to 35 in the preparation of a medicament for the simultaneous treatment of two or more diseases of non-alcoholic fatty liver disease, obesity, or type 2 diabetes. Use of a pharmaceutical composition comprising a GLP-1 fusion protein according to any one of 42.
(Aspect 51)
The use according to any one of aspects 47 to 50, wherein the pharmaceutical composition is administered intravenously or subcutaneously.
Claims (51)
a.軽鎖CDR1アミノ酸配列:配列番号1、配列番号4、配列番号7、配列番号10、配列番号13、及び配列番号15;
b.軽鎖CDR2アミノ酸配列:配列番号2、配列番号5、配列番号8、配列番号11、及び配列番号16;
c.軽鎖CDR3アミノ酸配列:配列番号3、配列番号6、配列番号9、配列番号12、配列番号14、及び配列番号17;
d.重鎖CDR1アミノ酸配列:配列番号18、配列番号23、及び配列番号26;
e.重鎖CDR2アミノ酸配列:配列番号19、配列番号21、配列番号24、配列番号27、及び配列番号29;並びに
f.重鎖CDR3アミノ酸配列:配列番号20、配列番号22、配列番号25、配列番号28、及び配列番号30
から選択される、前記抗体。 An antibody that specifically binds to human GIPR (GIPR antibody) comprising 1, 2, 3, 4, 5 or 6 amino acid sequences, where each amino acid sequence is independently listed below. Amino acid sequence:
a. Light chain CDR1 amino acid sequences: SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO: 15;
b. Light chain CDR2 amino acid sequences: SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11, and SEQ ID NO: 16;
c. Light chain CDR3 amino acid sequences: SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 14, and SEQ ID NO: 17;
d. Heavy chain CDR1 amino acid sequences: SEQ ID NO: 18, SEQ ID NO: 23, and SEQ ID NO: 26;
e. Heavy chain CDR2 amino acid sequences: SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 27, and SEQ ID NO: 29; and f. Heavy chain CDR3 amino acid sequence: SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, and SEQ ID NO: 30
The antibody selected from
a.軽鎖CDR1アミノ酸配列:配列番号1、配列番号4、配列番号7、配列番号10、配列番号13、及び配列番号15;並びに
b.重鎖CDR1アミノ酸配列:配列番号18、配列番号23、及び配列番号26から選択される、請求項1に記載の抗体。 The antibody comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain CDR1 amino acid sequences: SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO: 15; and b. 2. The antibody of claim 1, wherein the heavy chain CDR1 amino acid sequence is selected from: SEQ ID NO: 18, SEQ ID NO: 23, and SEQ ID NO: 26.
a.軽鎖CDR2アミノ酸配列:配列番号2、配列番号5、配列番号8、配列番号11、及び配列番号16;並びに
b.重鎖CDR2アミノ酸配列:配列番号19、配列番号21、配列番号24、配列番号27、及び配列番号29
から選択される、請求項1又は2に記載の抗体。 The antibody comprises or further comprises one or two amino acid sequences, wherein each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain CDR2 amino acid sequences: SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11, and SEQ ID NO: 16; and b. Heavy chain CDR2 amino acid sequence: SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 27, and SEQ ID NO: 29
The antibody according to claim 1 or 2, selected from:
a.軽鎖CDR3アミノ酸配列:配列番号3、配列番号6、配列番号9、配列番号12、配列番号14、及び配列番号17;並びに
b.重鎖CDR3アミノ酸配列:配列番号20、配列番号22、配列番号25、配列番号28、及び配列番号30
から選択される、請求項1~請求項3のいずれか一項に記載の抗体。 The antibody comprises or further comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain CDR3 amino acid sequences: SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 14, and SEQ ID NO: 17; and b. Heavy chain CDR3 amino acid sequence: SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, and SEQ ID NO: 30
The antibody according to any one of claims 1 to 3, selected from:
(a)軽鎖CDR1アミノ酸配列:配列番号1;
軽鎖CDR2アミノ酸配列:配列番号2;
軽鎖CDR3アミノ酸配列:配列番号3;
重鎖CDR1アミノ酸配列:配列番号18;
重鎖CDR2アミノ酸配列:配列番号19;及び
重鎖CDR3アミノ酸配列:配列番号20;
(b)軽鎖CDR1アミノ酸配列:配列番号4;
軽鎖CDR2アミノ酸配列:配列番号5;
軽鎖CDR3アミノ酸配列:配列番号6;
重鎖CDR1アミノ酸配列:配列番号18;
重鎖CDR2アミノ酸配列:配列番号21;及び
重鎖CDR3アミノ酸配列:配列番号22;
(c)軽鎖CDR1アミノ酸配列:配列番号7;
軽鎖CDR2アミノ酸配列:配列番号8;
軽鎖CDR3アミノ酸配列:配列番号9;
重鎖CDR1アミノ酸配列:配列番号23;
重鎖CDR2アミノ酸配列:配列番号24;及び
重鎖CDR3アミノ酸配列:配列番号25;
(d)軽鎖CDR1アミノ酸配列:配列番号10;
軽鎖CDR2アミノ酸配列:配列番号11;
軽鎖CDR3アミノ酸配列:配列番号12;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号27;及び
重鎖CDR3アミノ酸配列:配列番号28;
(e)軽鎖CDR1アミノ酸配列:配列番号13;
軽鎖CDR2アミノ酸配列:配列番号11;
軽鎖CDR3アミノ酸配列:配列番号14;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号27;及び
重鎖CDR3アミノ酸配列:配列番号28;又は
(f)軽鎖CDR1アミノ酸配列:配列番号15;
軽鎖CDR2アミノ酸配列:配列番号16;
軽鎖CDR3アミノ酸配列:配列番号17;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号29;及び
重鎖CDR3アミノ酸配列:配列番号30
を含む、請求項1~請求項9のいずれか一項に記載の抗体。 The antibody is
(a) Light chain CDR1 amino acid sequence: SEQ ID NO: 1;
Light chain CDR2 amino acid sequence: SEQ ID NO: 2;
Light chain CDR3 amino acid sequence: SEQ ID NO: 3;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 18;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 19; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 20;
(b) Light chain CDR1 amino acid sequence: SEQ ID NO: 4;
Light chain CDR2 amino acid sequence: SEQ ID NO: 5;
Light chain CDR3 amino acid sequence: SEQ ID NO: 6;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 18;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 21; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 22;
(c) Light chain CDR1 amino acid sequence: SEQ ID NO: 7;
Light chain CDR2 amino acid sequence: SEQ ID NO: 8;
Light chain CDR3 amino acid sequence: SEQ ID NO: 9;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 23;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 24; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 25;
(d) Light chain CDR1 amino acid sequence: SEQ ID NO: 10;
Light chain CDR2 amino acid sequence: SEQ ID NO: 11;
Light chain CDR3 amino acid sequence: SEQ ID NO: 12;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 27; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 28;
(e) Light chain CDR1 amino acid sequence: SEQ ID NO: 13;
Light chain CDR2 amino acid sequence: SEQ ID NO: 11;
Light chain CDR3 amino acid sequence: SEQ ID NO: 14;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 27; and Heavy chain CDR3 amino acid sequence: SEQ ID NO: 28; or (f) Light chain CDR1 amino acid sequence: SEQ ID NO: 15;
Light chain CDR2 amino acid sequence: SEQ ID NO: 16;
Light chain CDR3 amino acid sequence: SEQ ID NO: 17;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 29; and Heavy chain CDR3 amino acid sequence: SEQ ID NO: 30
The antibody according to any one of claims 1 to 9, comprising:
軽鎖CDR1アミノ酸配列:配列番号15;
軽鎖CDR2アミノ酸配列:配列番号16;
軽鎖CDR3アミノ酸配列:配列番号17;
重鎖CDR1アミノ酸配列:配列番号26;
重鎖CDR2アミノ酸配列:配列番号29;及び
重鎖CDR3アミノ酸配列:配列番号30
を含む、請求項10に記載の抗体。 The antibody is
Light chain CDR1 amino acid sequence: SEQ ID NO: 15;
Light chain CDR2 amino acid sequence: SEQ ID NO: 16;
Light chain CDR3 amino acid sequence: SEQ ID NO: 17;
Heavy chain CDR1 amino acid sequence: SEQ ID NO: 26;
Heavy chain CDR2 amino acid sequence: SEQ ID NO: 29; and Heavy chain CDR3 amino acid sequence: SEQ ID NO: 30
11. The antibody of claim 10, comprising:
a.軽鎖可変ドメインアミノ酸配列:配列番号61、配列番号62、配列番号63、配列番号64、配列番号65、配列番号66、配列番号67、配列番号68、配列番号69、配列番号70、及び配列番号71;並びにいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるアミノ酸配列;並びに
b.重鎖可変ドメインアミノ酸配列:配列番号72、配列番号73、配列番号74、配列番号75、配列番号76、配列番号77、配列番号78、配列番号79、及び配列番号80;並びにいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるアミノ酸配列
から選択される、請求項1~請求項11のいずれか一項に記載の抗体。 The antibody comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain variable domain amino acid sequences: SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, and SEQ ID NO: 71; and an amino acid sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to one of any of the above sequences; and b. Heavy chain variable domain amino acid sequences: SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, and SEQ ID NO: 80; and any of the above. 12. An antibody according to any one of claims 1 to 11, selected from amino acid sequences that are at least 80%, at least 85%, at least 90%, or at least 95% identical to one of the sequences.
a.軽鎖可変ドメインをコードするポリヌクレオチド配列:配列番号81、配列番号82、配列番号83、配列番号84、配列番号85、配列番号86、配列番号87、配列番号88、配列番号89、配列番号90、及び配列番号91;並びにいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるポリヌクレオチド配列;並びに
b.重鎖可変ドメインをコードするポリヌクレオチド配列:配列番号92、配列番号93、配列番号94、配列番号95、配列番号96、配列番号97、配列番号98、配列番号99、及び配列番号100;並びにいずれかの上記の配列の1つと少なくとも80%、少なくとも85%、少なくとも90%、又は少なくとも95%同一であるポリヌクレオチド配列から選択される、請求項1~請求項12のいずれか一項に記載の抗体。 The polynucleotide sequence encoding the antibody comprises one or two polynucleotide sequences, where each polynucleotide sequence independently comprises a polynucleotide sequence listed below:
a. Polynucleotide sequences encoding light chain variable domains: SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 , and SEQ ID NO: 91; and a polynucleotide sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to one of any of the above sequences; and b. Polynucleotide sequences encoding heavy chain variable domains: SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, and SEQ ID NO: 100; 13. A polynucleotide sequence according to any one of claims 1 to 12 selected from polynucleotide sequences that is at least 80%, at least 85%, at least 90%, or at least 95% identical to one of the above-mentioned sequences. antibody.
a.軽鎖定常ドメインアミノ酸配列:配列番号101及び配列番号102;並びに
b.重鎖定常ドメインアミノ酸配列:配列番号103、配列番号104及び配列番号124
から選択される、請求項1~請求項20のいずれか一項に記載の抗体。 The antibody comprises one or two amino acid sequences, where each amino acid sequence is independently an amino acid sequence listed below:
a. Light chain constant domain amino acid sequences: SEQ ID NO: 101 and SEQ ID NO: 102; and b. Heavy chain constant domain amino acid sequence: SEQ ID NO: 103, SEQ ID NO: 104 and SEQ ID NO: 124
The antibody according to any one of claims 1 to 20, selected from:
a.ヒトGIPRに結合する際に、参照GIPR抗体と同じか又はそれより良好なKdを提供すること;
b.GIPによって活性化されるヒトGIPRに拮抗する際に、参照GIPR抗体と同じか又はそれより良好なIC50を提供すること;及び
c.ヒトGIPRに対して参照GIPR抗体と結合に関して交差競合すること
を含む、請求項1~請求項28のいずれか一項に記載の抗体。 The antibody has one or more of the following properties:
a. provide the same or better Kd in binding to human GIPR than a reference GIPR antibody;
b. providing an IC 50 equal to or better than a reference GIPR antibody in antagonizing human GIPR activated by GIP; and c. 29. An antibody according to any one of claims 1 to 28, which comprises cross-competing for binding with a reference GIPR antibody to human GIPR.
ペプチドリンカーを介して、GLP-1フラグメントのカルボキシ末端が、GIPR抗体の軽鎖のアミノ末端に融合され:N’-GLP-1-リンカー-R-C’;
ペプチドリンカーを介して、GLP-1フラグメントのカルボキシ末端が、GIPR抗体の重鎖のアミノ末端に融合され:N’-GLP-1-リンカー-R-C’;
ここで:N’が、前記融合タンパク質のポリペプチド鎖のアミノ末端を表し、C’が、前記融合タンパク質のポリペプチド鎖のカルボキシ末端を表し、GLP-1が、GLP-1フラグメントを表し、Rが、請求項1~34のいずれか一項に記載のGIPR抗体の軽鎖又は重鎖のアミノ酸配列を表し、かつリンカーが、ポリペプチドリンカーを表す、請求項35に記載の融合タンパク質。 The GIPR antibody, GLP-1 fragment and peptide linker are fused to form the fusion protein in one of the following ways:
The carboxy terminus of the GLP-1 fragment is fused to the amino terminus of the light chain of the GIPR antibody via a peptide linker: N'-GLP-1-linker-RC';
The carboxy terminus of the GLP-1 fragment is fused to the amino terminus of the heavy chain of the GIPR antibody via a peptide linker: N'-GLP-1-linker-RC';
where: N' represents the amino terminus of the polypeptide chain of said fusion protein, C' represents the carboxy terminus of the polypeptide chain of said fusion protein, GLP-1 represents a GLP-1 fragment, and R 36. The fusion protein according to claim 35, wherein represents the amino acid sequence of the light chain or heavy chain of the GIPR antibody according to any one of claims 1 to 34, and the linker represents a polypeptide linker.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910882351.2A CN112521501A (en) | 2019-09-18 | 2019-09-18 | GIPR antibody and fusion protein thereof with GLP-1, and pharmaceutical composition and application thereof |
CN201910882351.2 | 2019-09-18 | ||
PCT/CN2020/115483 WO2021052349A1 (en) | 2019-09-18 | 2020-09-16 | Gipr antibody and fusion protein between same and glp-1, and pharmaceutical composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022549172A JP2022549172A (en) | 2022-11-24 |
JPWO2021052349A5 true JPWO2021052349A5 (en) | 2023-09-27 |
Family
ID=74883118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022517452A Pending JP2022549172A (en) | 2019-09-18 | 2020-09-16 | GIPR Antibodies and Fusion Proteins Thereof with GLP-1, and Pharmaceutical Compositions and Uses Thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220411520A1 (en) |
EP (1) | EP4063385A4 (en) |
JP (1) | JP2022549172A (en) |
KR (1) | KR20220063221A (en) |
CN (3) | CN112521501A (en) |
AU (1) | AU2020350715A1 (en) |
CA (1) | CA3154756A1 (en) |
MX (1) | MX2022003251A (en) |
TW (1) | TW202116803A (en) |
WO (1) | WO2021052349A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4352104A1 (en) * | 2021-06-09 | 2024-04-17 | Swiftnovo Therapeutics Inc. | Therapeutics and methods for treating or ameliorating metabolic disorders |
CN117659189A (en) * | 2022-09-08 | 2024-03-08 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein thereof with FGF21, and pharmaceutical composition and application thereof |
WO2024080650A1 (en) * | 2022-10-12 | 2024-04-18 | 서울대학교병원 | Composition and method for predicting sulfonylurea dependency using gipr marker |
WO2024094076A1 (en) * | 2022-11-02 | 2024-05-10 | 苏州康宁杰瑞生物科技有限公司 | Gipr binding protein and use thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
CA2146559A1 (en) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methods of preparing soluble, oligomeric proteins |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
SE9802080D0 (en) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein |
EP1306091A3 (en) | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation of beta cell proliferation |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
CN104080767A (en) * | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | Novel GLP-1 receptor modulators |
CN104371019B (en) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | It is a kind of can with GLP-1R specifically bind antibody and its with the fused protein of GLP-1 |
WO2017112824A2 (en) * | 2015-12-23 | 2017-06-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
JOP20190177A1 (en) * | 2017-01-17 | 2019-07-16 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
CN110831969B (en) * | 2017-06-20 | 2024-06-21 | 安进公司 | Methods of treating or ameliorating metabolic disorders using a combination of a Gastric Inhibitory Peptide Receptor (GIPR) binding protein and a GLP-1 agonist |
WO2018237095A1 (en) * | 2017-06-21 | 2018-12-27 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
CN117003874A (en) * | 2018-03-20 | 2023-11-07 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein of GIPR antibody and GLP-1, and pharmaceutical composition and application thereof |
-
2019
- 2019-09-18 CN CN201910882351.2A patent/CN112521501A/en active Pending
-
2020
- 2020-09-16 EP EP20866016.7A patent/EP4063385A4/en active Pending
- 2020-09-16 CN CN202080065099.7A patent/CN114641495A/en active Pending
- 2020-09-16 CN CN202310832321.7A patent/CN116942811A/en active Pending
- 2020-09-16 JP JP2022517452A patent/JP2022549172A/en active Pending
- 2020-09-16 AU AU2020350715A patent/AU2020350715A1/en active Pending
- 2020-09-16 CA CA3154756A patent/CA3154756A1/en active Pending
- 2020-09-16 US US17/761,128 patent/US20220411520A1/en active Pending
- 2020-09-16 MX MX2022003251A patent/MX2022003251A/en unknown
- 2020-09-16 KR KR1020227012130A patent/KR20220063221A/en unknown
- 2020-09-16 WO PCT/CN2020/115483 patent/WO2021052349A1/en unknown
- 2020-09-17 TW TW109132123A patent/TW202116803A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11566071B2 (en) | Nucleic acid molecules encoding anti-GPRC5D antibodies | |
JP7199494B2 (en) | Humanized and Chimeric Monoclonal Antibodies Against CD47 | |
AU2020201323B2 (en) | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof | |
CN102369214B (en) | Trivalent, bispecific antibody | |
JP2021525080A5 (en) | ||
JPWO2019129221A5 (en) | ||
JP2019520797A5 (en) | ||
JP2017536354A5 (en) | ||
JP7543247B2 (en) | Monoclonal antibody against human Tim-3 | |
BR112021008454A2 (en) | HUMANIZED ANTIBODIES AGAINST C-KIT | |
RU2013125459A (en) | ANTIBODIES AGAINST c-Met RECEPTOR PROTEIN | |
JP2017514515A5 (en) | ||
JPWO2019246003A5 (en) | ||
IL292780A (en) | New 4-1bbl trimer-containing antigen binding molecules | |
RU2019121106A (en) | IMMUNOTHERAPY WITH THE APPLICATION OF ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | |
JP2020513759A5 (en) | ||
JP2022521305A (en) | Anti-PD-L1 antibody and its use | |
CN110662768B (en) | Therapeutic anti-CD 40 ligand antibodies | |
JP2020502233A5 (en) | ||
JPWO2021052349A5 (en) | ||
TW202330627A (en) | Bispecific antibodies specifically binding to cd47 and her2, and uses thereof | |
JPWO2020180819A5 (en) | ||
JPWO2022111425A5 (en) | ||
JPWO2019179424A5 (en) | ||
JPWO2020073131A5 (en) |